Top in ID: COVID-19 transmission, vaccine trials

The CDC added and then removed an update on its website about airborne spread of SARS-CoV-2. It was the top story in infectious disease last week.

Another top story was about the implications of stopping and restarting COVID-19 vaccine trials.

Read these and more top stories in infectious disease below:

CDC adds, then removes mention of airborne spread of SARS-CoV-2 on website

The CDC added and then removed a note on its website that said SARS-CoV-2 is commonly spread via airborne transmission, saying that the update was part of new guidance that is still under review and was posted by mistake. Read more.

Q&A: Implications of stopping and restarting COVID-19 vaccine trials

Earlier this month, phase 3 trials for AstraZeneca’s COVID-19 vaccine candidate were halted due to a suspected serious adverse reaction in a participant from the United Kingdom. The trials have since resumed in the U.K. Read more.

Risk for nosocomial COVID-19 low under strict control measures, study suggests

In the early months of the pandemic, a Boston hospital with an infection prevention program that included dedicated COVID-19 units with airborne infection isolation rooms recorded just two cases of nosocomial COVID-19, a study found. Read more.

Study shows similar hospitalization, ICU admission rates among kids with COVID-19, flu

In a single-center study, researchers observed no significant differences in mechanical ventilator use, hospitalization or ICU admission rates among children with COVID-19 compared with children with influenza. Read more.

Phase 3 trial begins for one-dose COVID-19 vaccine candidate

Johnson & Johnson announced the start of a phase 3 trial that will enroll up to 60,000 people to study the safety and efficacy of its single-dose COVID-19 vaccine candidate. Read more.